An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BTD-001 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
Price : $35 *
At a glance
- Drugs Pentylenetetrazole (Primary)
- Indications Hypersomnia; Narcolepsy
- Focus Pharmacokinetics
- Acronyms HV103
- Sponsors Balance Therapeutics
- 20 Oct 2017 Status changed from active, no longer recruiting to completed.
- 19 Jun 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Apr 2017 New trial record